5th GPCRs-Targeted Drug Discovery Summit

Memo

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. With rapid advances in structural biology, computation, and screening, the race is on to validate new GPCRs, understand dynamic activation mechanisms, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection. Returning as the only industry-led meeting dedicated to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda featuring new expert voices, and fresh insights spanning the latest targets, tools, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights, build collaborations, and accelerate next-generation therapeutics from discovery to clinic. URLs:Tickets: https://go.evvnt.com/3386385-2?pid=5569Brochure: https://go.evvnt.com/3386385-3?pid=5569 Date and Time: Tuesday, 28 April 2026 at 08:00 - Thursday, 30 April 2026 at 17:00 Venue details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education) Prices:Conference Only - Primary Pricing: USD 3099.00,Conference + Focus Day - Primary Pricing: USD 4397.00,Conference Only - Discounted: USD 2699.00,Conference + Focus Day - Discounted: USD 3797.00,Conference Only - Vendor: USD 3799.00,Conference + Focus Day - Vendor: USD 5297.00 Speakers: Sameer Soi, VP, Data and AI, Abalone Bio, Danyal Butt, Associate Director, Abbvie, Christopher Roth, Senior Vice President - Research, Abilita Therapeutics, Shuguang Yuan, Cofounder, Alphamol, Glenn Short, Chief Scientific Officer, Atai Life Sciences, Tanweer Khan, Senior Director and Head Of Discovery Chemistry, Atai Life Sciences, David Alvin Cooper, Chief Executive Officer, Biagon, Hariprasad Vankayalapati, Chief Scientific Officer, Biolexis Therapeutics, Christel Menet, Chief Scientific Officer, Confo Therapeutics, Laurent Sabbagh, Scientific Director, Domain Therapeutics, Jonathan Gilbert, Senior Director, Ecosystem Growth – TuneLab, Eli Lilly, Chris Dockendorff, Chief Scientific Officer and Chief Executive Officer, Function Therapeutics, Ye Che, Senior Director, GSK, Andrew Kruse, Professor - Biological Chemistry and Molecular Pharmacology, Harvard Medical School, William Barnes, Executive Director, Head of GPCR Biology, Iambic Therapeutics, Aurelien Rizk, Chief Scientific Officer, InterAx Biotech, Zohar Barbash, Chief Technology Officer, Lembas, Marcin Paduch, Vice President, Platform Discovery, Metaphore Biotechnologies, Frances Anastassacos, Co-Founder, Nabla Bio, Inc., Hideaki Yano, Assistant Professor, Northeastern University, Matthew Albert, Vice President - Translational Sciences and Early Clinical Development, Octant, Steven Charlton, Chief Scientific Officer, OMass Therapeutics, Manel Kraeim Merabet, Chief Development Officer, Skymab Biotherapeutics, Ajay Yekkirala, Co-Founder, Senior Vice President and Head, Discovery and Development, Superluminal Medicines, John Diener, Senior Vice President, Tectonic Therapeutics, Lauren Slosky, Assistant Professor, University of Minnesota, Makaía Papasergi- Scott, Assistant Professor, University of Rochester Medical Center